BCPC
Basic MaterialsBalchem Corporation · Chemicals - Specialty · $5B
What is Balchem Corporation?
Balchem Corporation is a specialty ingredients company serving nutritional, food, pharmaceutical, and animal health markets across the United States and internationally. Founded in 1986 and headquartered in Montvale, New Jersey, it operates through three focused business segments.
Balchem develops and manufactures specialty performance ingredients sold to food and beverage producers, animal nutrition companies, and healthcare sterilization customers. Revenue flows from three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The company earns by supplying technically differentiated ingredients — such as microencapsulated nutrients and choline-based products — that customers embed directly into their own formulations and end products.
Balchem was founded in 1986 and is headquartered in Montvale, New Jersey.
- Microencapsulation and encapsulated nutrient delivery systems
- Choline nutrients and mineral amino acid chelates for human and animal health
- Ethylene oxide sterilization products for medical devices
- Spray-dried powders, blended lipid systems, and flavor delivery platforms
Is BCPC a Good Stock to Buy?
UQS Score rates BCPC as Good overall, reflecting a balanced profile with meaningful strengths and some areas worth monitoring.
The Risk pillar stands out as the clearest strength, suggesting Balchem carries a conservative financial profile relative to sector peers. Quality also registers as Good, pointing to consistent operational execution across its three business segments.
Valuation is flagged as Elevated, meaning the market may already be pricing in a favorable outlook — leaving less room for error. Growth and Moat both sit at Neutral, indicating neither a strong competitive barrier nor an accelerating expansion story at this time.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BCPC pay dividends?
Yes — Balchem Corporation pays a dividend.
Balchem pays a regular dividend, which is relatively uncommon among specialty ingredient companies of its size. This reflects the company's stable cash generation and management's confidence in sustaining returns to shareholders. Income-oriented investors may find the dividend cadence appealing, though the Elevated Valuation label is worth weighing alongside yield expectations.
When does BCPC report earnings?
Balchem Corporation reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Across recent reporting periods, Balchem has demonstrated steady operational performance across its Human Nutrition, Animal Nutrition, and Specialty Products segments. Results have generally reflected the company's positioning in stable, recurring-demand end markets rather than high-cyclicality commodity exposure.
For the most recent quarter's results and guidance commentary, visit Balchem's investor relations page directly.
BCPC Price History
+37.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Balchem Corporation?
Based on Balchem Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BCPC Long-term Outlook
Balchem's fundamental outlook is shaped by its Neutral Growth profile — suggesting steady rather than rapid expansion — paired with a Strong Risk profile that indicates the balance sheet and earnings quality provide a durable foundation. The Elevated Valuation label introduces a meaningful consideration: sustained premium pricing requires continued execution across all three segments. Specialty ingredient demand tied to nutrition and healthcare sterilization provides a relatively stable demand backdrop.
Growth drivers
- Expanding demand for functional and encapsulated ingredients in food, beverage, and supplement markets
- Growing animal nutrition market driven by livestock productivity and companion animal health trends
- Recurring sterilization demand from the medical device industry supporting the Specialty Products segment
Key risks
- Elevated valuation leaves limited margin of safety if segment growth disappoints
- Competitive pressure in specialty ingredients from larger diversified chemical companies
- Input cost volatility in raw materials used across encapsulation and choline production
BCPC vs Peers
Balchem operates in the specialty chemicals and ingredients space alongside several peers that serve overlapping end markets.
NewMarket focuses on petroleum additive chemistry, giving it a different end-market exposure than Balchem's nutrition and healthcare-oriented ingredient portfolio.
Axalta specializes in performance coatings for transportation and industrial applications, competing in specialty chemistry but with minimal overlap in nutrition or sterilization markets.
Sensient is the closest peer, supplying specialty flavors, fragrances, and ingredient systems to food and beverage producers — directly overlapping with Balchem's Human Nutrition & Health segment.
Frequently Asked Questions
What does Balchem Corporation do?
Balchem develops and sells specialty performance ingredients across three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Its core technologies include microencapsulation, choline nutrients, and ethylene oxide sterilization products used by food producers, animal health companies, and medical device sterilization customers.
Does BCPC pay dividends?
Yes, Balchem pays a regular dividend. The company's stable cash generation from recurring ingredient demand supports this payout. Investors should review the current yield and payout history on Balchem's investor relations page, as dividend amounts can change over time.
When does BCPC report earnings?
Balchem reports earnings quarterly, in line with standard US-listed company practice. Specific upcoming dates are not covered by our data source. Check Balchem's investor relations page or a financial calendar service for the next scheduled release.
Is BCPC a good stock to buy?
UQS Score rates BCPC as Good overall. The Risk pillar is Strong and Quality is Good, reflecting stable operations. However, the Valuation pillar is Elevated, which means the stock may already reflect a lot of positive expectations. The full pillar breakdown is available to UQS Pro members.
Is BCPC overvalued?
The UQS Valuation pillar for BCPC is rated Elevated, suggesting the current market price may be pricing in an optimistic scenario relative to fundamentals. This does not mean the stock will decline, but it does indicate a reduced margin of safety compared to more attractively valued peers.
How does BCPC compare to its competitors?
Among its closest peers, Sensient Technologies is the most direct competitor in specialty food and beverage ingredients. NewMarket and Axalta operate in adjacent specialty chemical niches with less direct overlap. Balchem's differentiation lies in its microencapsulation technology and choline-based nutrition platforms.
What is BCPC's market cap bracket?
Balchem Corporation is classified as a mid-cap company. This places it in a segment of the market that often balances growth potential with more established operations than smaller peers, though with less scale than large-cap specialty chemical companies.
Who founded Balchem Corporation?
Balchem was founded in 1986. Detailed founding history, including the names of original founders, is publicly available through Balchem's corporate history disclosures and financial filings.
Is BCPC a long-term quality indicator?
From a quality standpoint, BCPC's Good Quality pillar and Strong Risk profile suggest the business has durable operational characteristics. Long-term investors should weigh these strengths against the Elevated Valuation and Neutral Growth labels, which temper the near-term upside case. Full analysis is available to Pro members.
What is the main competitive advantage of Balchem Corporation?
Balchem's core advantage lies in its proprietary microencapsulation and chelation technologies, which are embedded into customers' own products and formulations. This creates switching costs and technical barriers. However, the UQS Moat pillar currently sits at Neutral, suggesting this advantage is not yet rated as wide relative to the broader sector.
Unlock Full BCPC Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for BCPC
- ✓Access full financial metrics including margins, returns, and valuation ratios
- ✓Compare BCPC side-by-side with Sensient, NewMarket, and other peers
- ✓Track pillar changes over time as new earnings data is released
- ✓Screen for similar mid-cap specialty ingredient stocks using UQS filters
Pro Analysis
BCPC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 59.5 | 69.5 | 46.0 | 60.7 | 86.4 | 36.7 | 0.0 |
| May 22, 2026 | 59.5 | 69.5 | 46.0 | 60.7 | 86.4 | 36.6 | 0.0 |
| May 21, 2026 | 59.5 | 69.5 | 46.0 | 60.7 | 86.4 | 36.7 | -0.1 |
| May 19, 2026 | 59.6 | 69.5 | 46.0 | 60.7 | 86.4 | 37.5 | 0.0 |
| May 16, 2026 | 59.6 | 69.5 | 46.0 | 60.7 | 86.4 | 37.6 | 0.0 |
| May 15, 2026 | 59.6 | 69.5 | 46.0 | 60.7 | 86.4 | 37.4 | 0.0 |
| May 14, 2026 | 59.6 | 69.5 | 46.0 | 60.7 | 86.4 | 37.6 | +0.1 |
| May 13, 2026 | 59.5 | 69.5 | 46.0 | 60.1 | 86.4 | 38.0 | -0.1 |
| May 12, 2026 | 59.6 | 69.5 | 46.0 | 60.1 | 86.4 | 38.1 | +0.1 |
| May 11, 2026 | 59.5 | 69.5 | 46.0 | 60.1 | 86.4 | 37.8 | +1.3 |
BCPC — Pillar Breakdown
Quality
— 69.5/100 (25%)Balchem Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 60.7/100 (20%)Balchem Corporation demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 86.4/100 (15%)Balchem Corporation carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 36.7/100 (15%)Balchem Corporation has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)Balchem Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BCPC.
Score Composition
Financial Data
More Stock Analysis
How is the BCPC UQS Score Calculated?
The UQS (Unified Quality Score) for Balchem Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Balchem Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Balchem Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.